Werewolf Therapeutics, Inc.
HOWL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001785530
In the last 90 days, Werewolf Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 45 institutions reported holding it in 13F filings for Q2 2026, worth $3.91M in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Werewolf Therapeutics, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Of which not filed for Q2 2022 | Q2 2022 | Change |
|---|---|---|---|---|
| Holders | 49 | 1 | 46 | −2 |
| Shares | 19.0M | 3.95K | 19.1M | +56.4K (+0.3%) |
| Value | $83.5M | $17.0K | $78.0M | −$5.50M (−6.6%) |
1 institution that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (14)
Institutions that held Werewolf Therapeutics, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Laurion Capital Management LP | 535,160 | $2.19M | 0.09% |
| Oasis Management Co Ltd. | 246,305 | $1.01M | 0.18% |
| Rubric Capital Management LP | 204,996 | $838.0K | 0.04% |
| Ergoteles LLC | 129,000 | $528.0K | 0.02% |
| Bridgeway Capital Management, LLC | 36,211 | $148.0K | 0.00% |
| Qube Research & Technologies Ltd | 22,535 | $92.0K | 0.00% |
| Bailard, Inc. | 21,200 | $87.0K | 0.00% |
| Renaissance Technologies LLC | 16,800 | $69.0K | 0.00% |
| Cubist Systematic Strategies, LLC | 13,250 | $54.0K | 0.00% |
| Y-Intercept (Hong Kong) Ltd | 11,124 | $45.0K | 0.01% |
| Credit Suisse AG | 14 | $0 | 0.00% |
| Group One Trading, L.P. | 15 | $0 | 0.00% |
| Glassman Wealth Services | 5 | $0 | 0.00% |
| Ellevest, Inc. | 31 | $0 | 0.00% |
Sold out (16)
Institutions that held Werewolf Therapeutics, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Migdal Insurance & Financial Holdings Ltd. | 187,500 | $825.0K |
| Bank of New York Mellon Corp | 68,338 | $301.0K |
| Charles Schwab Investment Management Inc | 60,646 | $267.0K |
| Granite Point Capital Management, L.P. | 55,000 | $242.0K |
| Evercore Wealth Management, LLC | 46,500 | $205.0K |
| Rhumbline Advisers | 22,550 | $99.0K |
| Citadel Advisors LLC | 20,144 | $89.0K |
| Two Sigma Investments, LP | 15,180 | $67.0K |
| Deutsche Bank AG | 14,349 | $63.0K |
| American International Group, Inc. | 13,111 | $58.0K |
| California State Teachers Retirement System | 11,286 | $50.0K |
| Amalgamated Bank | 3,946 | $17.0K |
| Legal & General Group Plc | 2,613 | $11.0K |
| Ameritas Investment Partners, Inc. | 2,041 | $9.00K |
| STRS Ohio | 1,800 | $7.00K |
| Nuveen Asset Management, LLC | 36,879 | – |
Not filed for Q2 2022 yet (1)
Institutions that held Werewolf Therapeutics, Inc. at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Amalgamated Financial Corp. | 3,946 | $17.0K |